Introduction Current guidelines recommend that patients with cerebral venous thrombosis
(CVT) should be treated with vitamin K antagonists (VKAs) for 3–12 months. Direct oral …

We are here to review the efficacy and safety of direct oral anticoagulants (DOACs) in the
treatment of Cerebral Venous Thrombosis (CVT). A search strategy was developed with a …

Objectives Current guidelines do not recommend direct oral anticoagulants (DOACs) to treat
cerebral venous thrombosis (CVT) despite their benefits over standard therapy. We …

Background: High level evidence for direct oral anticoagulants (DOACs) in patients with
cerebral venous thrombosis is lacking. We performed a systematic review and meta-analysis …

Vitamin K antagonists (VKAs) are the standard oral anti‐coagulant treatment for patients with
cerebral venous thrombosis (CVT). However, the direct oral anti‐coagulants (DOACs) …

Cerebral venous thrombosis (CVT) causes significant disability and mortality. Current
guidelines for CVT management support the initial use of unfractionated heparin or low …

Abstract Background Direct oral anticoagulants (DOACs) have entered the treatment
paradigms of various conditions based upon large randomized controlled trials. However …

Background: Cerebral venous thrombosis (CVT) is an uncommon neurological condition
usually treated with heparin followed by oral vitamin K antagonists (VKAs). In patients with …

Background: A small randomized controlled trial suggested that dabigatran may be as
effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to …

Cerebral venous thrombosis (CVT) is caused by partial or complete occlusion of the major
cerebral venous sinuses or the smaller feeding cortical veins which predispose to the risk of …